ProCE Banner Activity

Should PARP Inhibitors be Used Alone or in Combinations for Ovarian Cancer? The Influence of Patient and Disease Factors

Slideset Download
Download this slideset on potential of using PARP inhibitor monotherapy or in combination in patients with ovarian cancer.

Released: July 01, 2021

Expiration: June 30, 2022

No longer available for credit.

Share

Faculty

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France